**Fig. 1**




Fig. 2

3/20




Fig. 3

4/20




Fig. 4

5/20




Fig. 5a




Fig. 5b

6/20




Fig. 6

7/20




Fig. 7

8/20

ELISA OF HUMAN MMP-9:TIMP-1 IN PLASMA




Fig. 8

9/20

**ELISA OF FREE (NON-COMPLEXED)
HUMAN TIMP-1 IN PLASMA**




Fig. 9

10/20

Antibody tests:
Polyclonal antiMMP9 as catching
MAC19 as detection




Fig. 10

Antibody tests:
Polyclonal antiMMP9 as catching
MAC15 as detection





Fig. 11

12/20

Poly/MAC 19 assay - recovery in Citrate and EDTA plasma



Intra-assay variation: 9,6% for 24 triplicate measurements of control plasma pool

Fig. 12

ROC for colorectal cancer




Fig. 13

ROC for colorectal cancer/Dukes A+B




Fig. 14

15/20




Fig. 15

TIMP-1 levels ($\mu\text{g/L}$, log scale) in EDTA plasma from different patient groups compared to healthy donor samples.




Fig. 16

17/20





Fig. 17

**Fig. 18**

19/20

ROC for primary breast cancer





Fig. 19

20/20

TIMP-1 in citrate plasma from healthy females (n=87)
and advanced breast cancer patients (n=19)



	Median TIMP-1	Mean +-sd
Breast cancer patients	236 µg/L	292 +- 331 µg/L
Healthy blood donors	62.0 µg/L	63.5 +-10.5 µg/L

Fig. 20